%0 Journal Article
%T Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease.
%A Chen J
%A Farraj RA
%A Limonta D
%A Tabatabaei Dakhili SA
%A Kerek EM
%A Bhattacharya A
%A Reformat FM
%A Mabrouk OM
%A Brigant B
%A Pfeifer TA
%A McDermott MT
%A Ussher JR
%A Hobman TC
%A Glover JNM
%A Hubbard BP
%J J Biol Chem
%V 299
%N 11
%D 2023 11 11
%M 37832873
暂无%R 10.1016/j.jbc.2023.105341
%X The emergence of severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019, has resulted in the largest pandemic in recent history. Current therapeutic strategies to mitigate this disease have focused on the development of vaccines and on drugs that inhibit the viral 3CL protease or RNA-dependent RNA polymerase enzymes. A less-explored and potentially complementary drug target is Nsp15, a uracil-specific RNA endonuclease that shields coronaviruses and other nidoviruses from mammalian innate immune defenses. Here, we perform a high-throughput screen of over 100,000 small molecules to identify Nsp15 inhibitors. We characterize the potency, mechanism, selectivity, and predicted binding mode of five lead compounds. We show that one of these, IPA-3, is an irreversible inhibitor that might act via covalent modification of Cys residues within Nsp15. Moreover, we demonstrate that three of these inhibitors (hexachlorophene, IPA-3, and CID5675221) block severe acute respiratory syndrome coronavirus 2 replication in cells at subtoxic doses. This study provides a pipeline for the identification of Nsp15 inhibitors and pinpoints lead compounds for further development against coronavirus disease 2019 and related coronavirus infections.